Diabetes 53:S186-S189, 2004 © 2004 by the American Diabetes Association, Inc.
ß-Cell Calcium-Independent Group VIA Phospholipase A2 (iPLA2ß)Tracking iPLA2ß Movements in Response to Stimulation With Insulin Secretagogues in INS-1 Cells
1 Mass Spectrometry Resource, Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri
Evidence that group VIA cytosolic calcium-independent phospholipase A2 (iPLA2ß) participates in ß-cell signal transduction includes the observations that inhibition of iPLA2ß with the bromoenol lactone suicide substrate suppresses glucose-stimulated insulin secretion and that overexpression of iPLA2ß amplifies insulin secretory responses in INS-1 insulinoma cells. Immunofluorescence analyses also reveal that iPLA2ß accumulates in the perinuclear region of INS-1 cells stimulated with glucose and forskolin. To characterize this phenomenon further, iPLA2ß was expressed as a fusion protein with enhanced green fluorescent protein (EGFP) in INS-1 cells so that movements of iPLA2ß are reflected by changes in the subcellular distribution of green fluorescence. Stimulation of INS-1 cells overexpressing iPLA2ß-EGFP induced greater insulin secretion and punctate accumulation of iPLA2ß-EGFP fluorescence in the perinuclear region. To determine the identity of organelles with which iPLA2ß might associate, colocalization of green fluorescence with fluorophores associated with specific trackers targeted to different subcellular organelles was examined. Such analyses reveal association of iPLA2ß-EGFP fluorescence with the ER and Golgi compartments. Arachidonate-containing plasmenylethanolamine phospholipid species are abundant in ß-cell endoplasmic reticulum (ER) and are excellent substrates for iPLA2ß. Arachidonic acid produced by iPLA2ß-catalyzed hydrolysis of their substrates induces release of Ca2+ from ER storesan event thought to participate in glucose-stimulated insulin secretion.
Phospholipase A2 (PLA2) is a diverse group of enzymes that catalyze hydrolysis of the sn-2 substituent from glycerophospholipid substrates to yield a free fatty acid and a 2-lysophospholipid (1,2). Among the PLA2s is an 84-kDa cytosolic PLA2 that does not require Ca2+ for catalysis and is designated group VIA cytosolic calcium-independent phospholipase A2 (iPLA2ß) (35). A role for iPLA2ß in signal transduction in insulin-secreting ß-cells is suggested by the observations that inhibition of iPLA2ß activity with the bromoenol lactone (BEL) suicide substrate of iPLA2ß suppresses insulin secretion, and overexpression of iPLA2ß amplifies glucose- and forskolin-stimulated insulin secretion from pancreatic islets and INS-1 insulinoma cells (6,7). Stimulation of iPLA2ß-overexpressing INS-1 cells with cAMP-elevating agents also induces translocation of iPLA2ß to the perinuclear region (7). This is of interest because glucose promotes both ß-cell insulin secretion and proliferation, and glucose-induced INS-1 cell mitogenesis is cAMP dependent (8). To characterize iPLA2ß subcellular movements further, we developed INS-1 cell lines that overexpress iPLA2ß as a fusion protein with enhanced green fluorescent protein (EGFP) so that green fluorescence associated with EGFP reflects the location of iPLA2ß. Simultaneous monitoring of florescence associated with various tracking molecules allowed us to identify specific subcellular organelles with which iPLA2ß associates when cells are stimulated.
Preparation of a construct for expressing iPLA2ß as a fusion protein with EGFP and selection of stably transfected clones. Full-length iPLA2ß cDNA was amplified by PCR using the following primer set: sense, 5' AGCTTCGAATTCATGCAGTTCTTTGGACGC-3, and antisense, 5'-TTCGATATCGGGAGATAGCAGCAGCTGG-3'. The amplified full-length iPLA2ß from the pMSCV-neo-iPLA2ß constructs were then subcloned into the pEGFP-N2 (Clontech, Palo Alto, CA) after the immediate early promoter of cytomegalovirus major and before EGFP coding sequences in the same code-reading frame with EGFP. The EGFP-N2 control vector and the construct encoding iPLA2ß-EGFP (FPN2) fusion protein were transfected into INS-1 cells with a Gene PORTER transfection system according to the manufactures instructions (Gene Therapy Systems, San Diego, CA). Stably transfected clones were selected using G418 (0.4 mg/ml). Stably transfected cells obtained with EGFP-N2 control vector and FPN2 construct are designed as N2 cells and FPN2 cells, respectively.
Preparation of INS-1 cell subcellular fractions and iPLA2ß enzymatic activity assay.
Immunoblotting analyses of iPLA2ß protein.
Insulin secretion.
Subcellular organelle tracking. For tracking of ER, mitochondria, or plasma membrane, cells were first washed and then incubated (37°C, 1 h) in medium containing no glucose and 0.1% BSA. That medium was then replaced with medium containing 2 mmol/l glucose and 2.5 µmol/l forskolin for up to 1 h. The ER tracker (Blue-White DPX, 600 nmol/l) or mitochondrial tracker (Deep Red 633, 100 nmol/l) was added during the final 30 min of incubation. The plasma membrane tracker (DiI D-282, 0.50 µmol/l) was added during the final 20 min of incubation. After various intervals, signals from these fluorophores were monitored.
Immunoblotting analyses of expression of the EGFP fusion protein in INS-1 cells. To demonstrate that transfection of INS-1 cells with the vector containing the iPLA2ß-EGFP construct causes overexpression of the fusion protein, cytosolic and membrane fractions were prepared from transfected INS-1 cells. Proteins in these fractions were analyzed by SDS-PAGE and transferred onto polyvinylidene difluoride membranes that were then used in immunoblotting analyses with antibodies directed against EGFP (Fig. 1A) or iPLA2ß (Fig. 1B). Subcellular fractions prepared from cells transfected with the EGFP vector (N2) alone express only the EGFP-immunoreactive bands of 26 kDa (Fig. 1A, lanes 2 and 4). Transfection with the iPLA2ß-EGFP fusion protein vector (FPN2) causes expression in both the cytosol and membrane fractions of an EGFP-immunoreactive protein with a molecular weight of 110115 kDa (Fig. 1A, lanes 1 and 3) that represents full-length iPLA2ß as a fusion protein. A second EGFP-immunoreactive band with a molecular weight of 9095 kDa is also observed in cytosol of FPN2 transfected cells (Fig. 1A, lane 1). This molecular weight corresponds to an iPLA2ß product of 6570 kDa plus the 26-kDa EGFP. Immunoblotting analyses with iPLA2ß antibody (Fig. 1B) yield results similar to those observed with the GFP antibody. An iPLA2ß-immunoreactive protein corresponding to an iPLA2ß-EGFP fusion protein is not observed in cells transfected with vector containing only the N2 construct (Fig. 1B, lanes 2 and 4), but such a 110- to 115-kDa protein is observed in cells transfected with the vector containing the iPLA2ß-EGFP construct (Fig. 1B, lanes 1 and 3).
iPLA2ß enzymatic activity in INS-1 cells overexpressing iPLA2ß as a fusion protein. To demonstrate that the FPN2-transfected cells express iPLA2ß enzymatic activity, cytosolic and membrane-associated iPLA2ß activities were assayed in the absence and presence of ATP or BEL. FPN2-transfected cells were found to express calcium-independent PLA2 activity in cytosol and membranes nearly four- to fivefold higher than that expressed in N2 cells (data not shown). The calcium-independent PLA2 activity in FPN2 cells is stimulated by ATP and inhibited by the BEL suicide substrate, as is the case for native iPLA2ß (3). These findings and those in Fig. 1 demonstrate that transfection of INS-1 cells with the iPLA2ß-EGFP fusion protein vector causes overexpression of an enzymatically active iPLA2ß protein.
Amplification of glucose-induced insulin secretion by forskolin.
Secretagogue-stimulated subcellular redistribution of iPLA2ß.
Secretagogue-stimulated redistribution of iPLA2ß to specific organelles.
Many potential biological functions have been proposed for the cytosolic calcium-independent iPLA2ß enzyme (3). Among the proposed functions are its participation in phospholipid remodeling in P388D1 macrophage-like cells (5,11), cell proliferation (12,13), apoptosis (3), and signal transduction in ß-cells and in other cells (12). In ß-cells, inhibition of iPLA2ß suppresses glucose-induced insulin secretion, and overexpression of the enzyme enhances secretion, but neither inhibition nor overexpression of iPLA2ß affects incorporation of fatty acids into ß-cell phospholipids (12). These findings indicate that iPLA2ß has a signaling role in insulin secretion but does not serve a housekeeping role in phospholipid remodeling in ß-cells. Immunofluorescence analyses using polyclonal antibodies directed against iPLA2ß also indicate that stimulation of ß-cells with insulin secretagogues cause redistribution of iPLA2ß within the ß-cell. There is accumulation of an iPLA2ß immunofluorescence signal in the perinuclear region of INS-1 insulinoma cells that are stimulated with glucose and the cAMP-elevating agent forskolin (7). To examine this phenomenon further by an approach not confounded by the potential cross-reactivity of iPLA2ß antibodies, iPLA2ß was overexpressed in INS-1 cells as a fusion protein with EGFP in the studies described here. The location of the fusion protein is reflected by green fluorescence associated with EGFP and facilitates tracking of the subcellular location of iPLA2ß. In INS-1 cells that overexpress iPLA2ß-EGFP, stimulation with glucose alone or in combination with forskolin induces the appearance of punctate accumulations of green fluorescence as a halo around the perinuclear region. Studies to identify subcellular organelles with which iPLA2ß associates were performed with fluorescent trackers targeted to specific organelles, and these experiments reveal colocalization of iPLA2ß-EGFP-associated green fluorescence with ER and Golgi markers. Because membranes of the nucleus and ER are contiguous (14,15), perinuclear accumulation of iPLA2ß is consistent with association with a subcellular compartment that is likely to include ER (15). Arachidonate-containing plasmenylethanolamine phospholipid molecular species are abundant in ß-cell ER and are excellent substrates for iPLA2ß (16). Arachidonic acid and lysophospholipids produced by iPLA2ß-catalyzed hydrolysis of these substrates induce Ca2+ release from ß-cell ER, which is thought to participate in induction of insulin secretion (16,17). Arachidonic acid hydrolyzed from plasmenylethanolamine molecular species (18) and/or arachidonate metabolites have been proposed to participate in the ß-cell secretory process (17,18), and stimulated association of iPLA2ß with a perinuclear membrane would cause release of arachidonic acid in close proximity to enzymes that catalyze eicosanoid generation and are located in the nuclear envelope and ER (19,20).
This research was supported by grants from the National Institutes of Health (R37-DK34388, P41-RR00954, P01-HL57278, P60-DK20579, and P30-DK56341) and by an Award (to S.R.) from the American Diabetes Association. The authors thank Alan Bohrer and Dr. Mary Wohltmann for expert technical assistance.
This article is based on a presentation at a symposium. The symposium and the publication of this article were made possible by an unrestricted educational grant from Les Laboratoires Servier. Address correspondence and reprint requests to Sasanka Ramanadham, Washington University School of Medicine, Department of Medicine, Box 8127, 660 S. Euclid Ave., St. Louis, MO 63110. E-mail: sramanad{at}im.wustl.edu Received for publication March 14, 2003 and accepted in revised form May 7, 2003
Abbreviations: BEL, bromoenol lactone; EGFP, enhanced green fluorescent protein; FITC, fluorescein isothiocyanate; iPLA2ß, group VIA cytosolic calcium-independent phospholipase A2; PLA2, phospholipase A2
This article has been cited by other articles:
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||